MarketPulse
O

$OCUL

2 articles found
2 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Ocular Therapeutix Plans June Investor Day Amid Promising AMD Trial Data

Ocular Therapeutix schedules June 17 investor day in NYC while reporting positive Week 52 data from SOL-1 Phase 3 trial of AXPAXLI for wet AMD treatment.
OCULPhase 3 trialInvestor Day
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Ocular Therapeutix to Release SOL-1 Phase 3 Results for Wet AMD Treatment

Ocular Therapeutix announces Phase 3 results for SOL-1 wet AMD treatment on February 17, 2026. AXPAXLI data presentation follows at Macula Society Annual Meeting.
OCULPhase 3 clinical trialbiopharmaceutical